Background
==========

Prostaglandin E~2~ plays a crucial role in inflammation, including pain, fever and tumorigenesis. Inflammatory cells, fibroblasts and epithelium are the main source of PGE~2~ throughout an immune response. There are four known receptors for PGE~2~, E type prostanoid receptors 1--4 (EP~1,2,3,4~). According to recent reports, the EP~4~ receptor seems to be a potential target of therapeutic treatment for attenuating inflammation as well as increased endothelial permeability.

Methods
=======

Primary human microvascular endothelial cells of the lung (HMVEC-L) were cultured and transfected using siRNA approach. The mRNA level of the EP~4~ receptor was determined using RT-PCR. EP~4~ receptor protein expression was evaluated via Western blotting and flow cytometry. Changes in electrical impedance were measured using an ECIS application. Morphological alterations were observed via immunofluorescent staining of β-catenin and F-actin. Cell cycle and apoptosis analysis were performed using flow cytometry.

Results
=======

The pulmonary microvascular endothelial cells express the PGE~2~ receptor EP~4~, which was shown by flow cytometry and Western blotting. In endothelial cells, EP~4~ receptor protein expression was down-regulated to less than 40% by using the siRNA transfection approach. Also, the mRNA level of the EP~4~ receptor was significantly down-regulated below 15% using siRNA transfection. In the endothelial impedance measurements, the EP~4~ agonist and PGE~2~-induced barrier enhancement was significantly suppressed in EP~4~ receptor-silenced cells. Morphological studies revealed that the thrombin-induced disruption of endothelial monolayers could be reversed by stimulation of EP~4~ receptors. Cell-cell contacts were enhanced and stress fibre formation was prevented by pre-treatment with PGE~2~ and an EP~4~-selective agonist. PGE~2~ and the EP~4~ agonist did not induce any changes in the endothelial cell cycle; however, EP~4~ receptor activation appeared to be protective against staurosporine-induced apoptosis. Apoptotic cells were determined in the sub-G~1~ phase of the cell cycle.

Conclusions
===========

These data suggest EP~4~ receptor agonists as potential therapeutic intervention for diseases with increased vascular permeability such as acute lung injury.
